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Maurizio Sessa 1,2*†, Gabriella di Mauro 1†, Annamaria Mascolo 1, Concetta Rafaniello 1,
Liberata Sportiello 1, Cristina Scavone 1‡ and Annalisa Capuano 1‡
1Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Section of Pharmacology “L. Donatelli”,
Department of Experimental Medicine, University of Campania “L. Vanvitelli”, Naples, Italy, 2Department of Drug Design and
Pharmacology, University of Copenhagen, Copenhagen, Denmark
Rationale: The aim of this study is to investigate if following the implementation of
the Regulation EU/1235/2010 and the Directive 2010/84/EU there was an increase of
individual case safety reports (ICSRs) deriving from a medication error, abuse, misuse,
overdose, or occupational exposure. Other objectives are the identification of drugs
mostly involved in such cases, to establish if the codification of aforementioned conditions
is performed correctly and, whenever codification errors exist, to identify predictors of
codification errors. Finally, we estimated themagnitude of these errors on signal detection
activities.
Methods: ICSRs sent through Campania Region (Italy) spontaneous reporting system
from July 2nd 2012 to December 31th 2017 were used as data source. A multivariable
logistic regression model was used to identify predictors of codification errors. Four
measures of disproportionality were used to investigate the magnitude of codification
errors on a known safety signal or rather the association between benzodiazepines
derivatives and abuse.
Results: In all, 358 (1.4%) out of 25610 ICSRs reported “non-normal use” of drugs,
mainly as cases of abuse. Drugs mostly involved in abuse were “Benzodiazepines
derivatives” (171/358; 47.8%). For medication errors instead, “Other antiseptics
and disinfectants” (9/358; 2.5%). At the first quality control, 125 (34.9%) out of
358 ICSRs did not have a codification of “non-normal use” or codifications were
performed wrongly. Codification errors included misclassification of abuse as overdose
(10/125; 8.0%) and misclassification of medication error as overdose (7/125; 5.6%)
or abuse (7/125; 5.6%). Compared to pharmaceutical companies, patients/citizens (as
reporters) had a 24.88 higher odd (Reporting Odds Ratio 24.88, 95%CI 1.82–449.95;
p-value: 0.02) of performing un-classification or misclassification of aforementioned
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codifications. Codification errors were associated with the underestimation of measure
of disproportionality’ estimates in the identification of the safety signal “Benzodiazepine
derivatives /abuse”.
Conclusion: In conclusion, this study found that in Campania Region (southern Italy)
there was an exponential increase of ICSR reporting “non-normal use,” mainly as cases
of abuse, with an improvable proportion of cases misclassified/unclassified. Moreover,
this study found that ICSRs sent by patients/citizens were associated with an increased
odd of un-classification or misclassification that had a relevant impact on signal detection
activities.
Keywords: medication errors, spontaneous reporting system, pharmacovigilance, abuse, overdose, occupational
exposure, misuse
INTRODUCTION
Despite accomplishments obtained by the European Member
States in terms of enhancements of National Pharmacovigilance
systems, the European Parliament and the European Council
(EC) in December 2010 approved the new Pharmacovigilance
legislation or rather the Regulation (EU) No. 1235/2010 and
the Directive 2010/84/EU that come into force on July 2nd
2012. These new legal provisions have radically changed the
European Pharmacovigilance landscape introducing rules
aimed to optimize and speed up the safety signal detection and
strengthen the current Pharmacovigilance system by making it
more robust and transparent for a better detection, assessment,
understanding, and prevention of adverse drug reactions or any
other drug-related problem (European Parliament, 2010a,b).
With the new Pharmacovigilance legislation, it was introduced
a new definition of an adverse event now defined as “any
unfavorable and unintended sign (e.g., an abnormal laboratory
finding), symptom, or disease temporally associated with the
use of a medicinal product” (European Medicine Agency,
2017). With the new definition of an adverse event, it became
possible to report those deriving from a medication error, abuse,
misuse, overdose, and occupational exposure. According to
Good Pharmacovigilance Practices (GVP)—Module VI (Rev 2)
TABLE 1 | Operative definitions of measures of disproportionality.
PRR = A
A+B
upslope C
C+D
Where:
ROR = A
B
upslopeC
D Abuse All other events
Benzodiazepine
derivatives
A B
All other drugs C D
RRR = A*
(
A+ B+ C+ D
)
upslope
(A+ B) *
(
A+ C
)
IC = log2
p(x,y)
p(x)p(y)
Where:
p(x) = probability that benzodiazepine derives
listed on ICSR;
p(y) = probability that abuse listed on ICSR;
p(y,x) = probability that benzodiazepine
derivatives-abuse combination listed on ICSR.
PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio; RRR, Relative Reporting
Ratio; IC, Information Component.
an occupational exposure “refers to the exposure to a medicinal
product, as a result of one’s professional or non-professional
occupation” and a misuse “refers to situations where the
medicinal product is intentionally and inappropriately used
not in accordance with the authorized product information.”
An abuse, instead, “corresponds to the persistent or sporadic,
intentional excessive use of a medicinal product, which is
accompanied by harmful physical or psychological effects”
and a medication error “refers to any unintentional error in
the prescribing, dispensing, or administration of a medicinal
product while in the control of the healthcare professional or
consumer.” Finally, an overdose “refers to the administration
of a quantity of a medicinal product given per administration
or cumulatively, which is above the maximum recommended
dose according to the authorized product information. Clinical
judgment should always be applied” (European Medicine
Agency, 2017). The European Commission introduced such
modifications in the optic of riskminimization aiming to increase
their detection to promote their preventability, especially in
spontaneous reports or rather spontaneous Individual case
safety reports (ICSRs). On a European level, spontaneous
ICSRs are collected from consumers (defined as a person
who is not a healthcare professional such as a patient, lawyer,
friend, relative of a patient or care) and healthcare professional
(defined as a medically-qualified person such as a physician,
dentist, pharmacist, nurse, coroner, or as otherwise specified by
local regulations; European Medicine Agency, 2017). In Italy,
consumers and healthcare professionals have three possible
ways to report an adverse reaction report. The first option for
a reporter is to send the aforementioned report to the local
pharmacovigilance manager (local health unit/hospital). The
second and third options are to report the adverse reaction
report directly to the national competent authority or to the
marketing authorization holder, respectively. To the best of
our knowledge, to date, in Italy, it is unknown if following
the implementation of the Regulation EU/1235/2010 and
the Directive 2010/84/EU there was an increase of cases
reporting medication errors, abuse, misuse, overdose, or
occupational exposure. Even less is known about drugs involved
in these cases and if the codification of aforementioned
conditions is performed correctly. Additionally, whenever
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TABLE 2 | Demographic characteristics, seriousness, and reporter qualification of ICSRs deriving from abuse, misuse, medication error and occupational exposure
recognized in Campania Region spontaneous reporting system from July 2nd 2012 to December 31th 2017.
Variable Level Abuse
(n =
297)
Medication error
(n = 31)
Misuse
(n = 2)
Overdose
(n = 28)
Total
(n =
358)
Gender Female 198 (66.7) 17 (54.8) 2 (100.0) 18 (64.3) 235 (65.6)
Male 99 (33.3) 14 (45.2) 0 (0.0) 10 (35.7) 123 (34.4)
Age mean (SD) 43.9 (18.9) 35.0 (32.1) 67.0 (15.6) 37.8 (24.1) 42.7 (20.9)
Seriousness Not defined 7 (2.4) 1 (3.2) 0 (0.0) 1 (3.6) 9 (2.5)
Not serious 96 (32.3) 15 (48.4) 1 (50.0) 18 (64.3) 130 (36.3)
Serious - death 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Serious - life threatening 23 (7.7) 1 (3.2) 0 (0.0) 0 (0.0) 24 (6.7)
Serious - other clinically
relevant condition
71 (23.9) 1 (3.2) 0 (0.0) 4 (14.3) 76 (21.2)
Serious - hospitalization 99 (33.3) 13 (41.9) 1 (50.0) 5 (17.9) 118 (33.0)
Reporter Anti-poison center 8 (2.7) 4 (12.9) 0 (0.0) 1 (3.6) 13 (3.6)
Hospital physician 173 (58.2) 19 (61.3) 0 (0.0) 12 (42.9) 204 (57.0)
Other healthcare
professionals
31 (10.4) 2 (6.5) 1 (50.0) 4 (14.3) 38 (10.6)
Patients/citizens 2 (0.7) 1 (3.2) 0 (0.0) 4 (14.3) 7 (2.0)
Pharmaceutical companies 8 (2.7) 1 (3.2) 0 (0.0) 0 (0.0) 9 (2.5)
Pharmacist 75 (25.3) 4 (12.9) 1 (50.0) 7 (25.0) 87 (24.3)
SD, standard deviation.
codification errors exist, it is unknown to which extent they
could influence signal detection activities. Given these gaps in
knowledge, to provide further insight on aforementioned
topics we investigated all adverse events deriving from
medication errors, abuse, misuse, overdose, and occupational
exposure among those reported through Campania Region
(an Italian Region of southern Italy with 6 million citizens)
spontaneous reporting system from July 2nd 2012 to December
31th 2017.
METHODS
Study Design
Passive pharmacovigilance project that includes a case series
of ICSRs reporting abuse, misuse, overdose, occupational
exposure and medication errors (World Health Organization,
2012).
Data Source
We retrieved from the Italian National database for
Pharmacovigilance (Rete Nazionale di Farmacovigilanza,
RNF) all ICSRs reported through Campania Region
spontaneous reporting system from July 2nd 2012 to
December 31th 2017. The Italian Medicine Agency (AIFA)
manages RNF that stores all ICSRs of suspected adverse drug
reactions that have been reported on the National territory.
Before being recorded in RNF, Local Pharmacovigilance
Managers (LPM) of local health units, hospitals, and
Scientific Institutes for Hospitalization and Care (IRCCS)
evaluates the quality of information reported in ICSRs and
retrieved missing information needed for a proper causality
assessment.
Case-By-Case Assessment
For each ICSR sent through Campania Region spontaneous
reporting system and recorded in RNF, Campania
Pharmacovigilance and Pharmacoepidemiology Regional
Centre (CPPRC) validates data included in ICSRs and performs
causality assessment for all drug-event couples using the Naranjo
algorithm. If discrepancies were identified, CPPRC proceeds
to reconciliation with both LPM and the reporter (through
LPM).
Validation of Abuse, Overdose, Misuse,
Medication Error, and Occupational
Exposure Codifications in ICSRS
From July 2nd 2012, for the purpose of this study, CPPRC
recorded in an ad-hoc database all ICSRs for which a
codification of abuse, overdose, misuse, medication errors,
and occupational exposure was needed. A codification
was considered as needed if personnel of CPPRC, by re-
evaluating the ICSR, found that the case was classifiable as
abuse, overdose, misuse, medication errors, or accidental
exposure as in accordance with the Good Pharmacovigilance
Practice (European Medicine Agency, 2017). We considered
a codification of abuse, overdose, misuse, medication
error, and occupational exposure as assigned erroneously
if it was not in accordance with a forementioned
Pharmacovigilance guidelines (European Medicine Agency,
2017).
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FIGURE 1 | (A) Trend of Individual Case Safety Reports (ICSRs) deriving from
abuse, medication error, misuse and overdose reported in Campania Region
spontaneous reporting system from July 2nd 2012 to December 31th 2017;
(B) percentage distribution trend of un-classification or misclassification of
cases identified using the same data source in the same study period.
Statistical Analyses
To provide an overview of the number of cases of abuse,
overdose, misuse, medication errors and occupational exposure
reported in Campania Region along with drugs reported as
suspected in these cases, we plotted the number of ICSRs
stratified by year. Drugs were grouped in chemical subgroup
according to the fourth level of the Anatomical Therapeutic
Chemical (ATC) classification system. Codification errors along
with representative examples were tabled. The number of
codification errors for abuse, overdose misuse, medication
error, and occupational exposure was stratified by year and it
was plotted. The percentage distributions of ADRs [grouped
by System Organ Class (SOC)] was plotted singularly for
abuse, misuse, medication error, and occupational exposure. For
descriptive purposes, clinical and demographic characteristics
of cases, seriousness, and outcome of ADRs and the type
of reporter stratified by abuse, overdose, misuse, medication
error, and occupational exposure were reported. Based on
the ICSR form available on the National territory, for the
outcome, six categories were used: resolution with sequelae,
unchanged clinical condition, recovered, improvement, death,
and not available. Seriousness was codified according to
the International Council on Harmonization E2D guidelines
(International Conference on Harmonisation E2D, 2018). A
multivariable logistic regression model was used to identify
predictors of codification errors among the year of reporting, age,
gender, the reporter qualification, suspected drugs (grouped as
shown in Supplementary Table 1), and ADRs (classified by SOC,
as shown in Supplementary Table 2). In particular, the reporting
odds ratio (ROR) with 95% confidence intervals (95%CI)
FIGURE 2 | Top-five drug classes reported in ICSRs deriving from (A) abuse,
(B) medication error, and (C) overdose that were sent through Campania
Region spontaneous system from July 2nd 2012 to December 31th 2017.
was computed (Rothman et al., 2004). For this analysis, we
considered a case as having a codification error if a codification
was not included (but it was needed) and if the codification
was assigned erroneously. To investigate the magnitude of
abuse’ codification errors on signal detection activities (abuse
was chosen because it was the most representative “non-
normal use” condition in ICSRs), we investigated a known
safety signal, or rather the association between benzodiazepines
derivatives and abuse (O’brien, 2005). In particular, for the
aforementioned safety signal, we tested four measures of
disproportionalities and in particular the Proportional Reporting
Ratio (PRR), the Reporting Odds Ratio (ROR), the Relative
Reporting Ratio (RRR), and the Information Component (IC)
with and without correcting codification errors (Wilson et al.,
2004; Van Holle and Bauchau, 2014; Böhm et al., 2016).
The PRR, ROR, RRR, and IC were computed as shown in
Table 1.
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FIGURE 3 | Top-five drugs reported in ICSRs deriving from (A) abuse, (B)
medication error, and (C) overdose that were sent through Campania Region
spontaneous system from July 2nd 2012 to December 31th 2017.
RESULTS
Overview of ICSRs Deriving From a
Medication Error, Abuse, Misuse,
Overdose, or Occupational Exposure
Among Those Reported Through
Campania Region Spontaneous Reporting
System
From July 2nd 2012 to December 31th 2017, 358 (1.4%) out
of 25610 ICSRs reported abuse, overdose, misuse, medication
error, or occupational exposure among those sent through
Campania Region spontaneous reporting system (Table 2,
Figure 1, Supplementary Figures 1–5). Drugs mostly involved
in abuse were “Benzodiazepines derivatives” (171/358; 47.8%)
and in particular alprazolam (40/171; 23.4%), lorazepam (30/171;
17.5%), and delorazepam (26/171; 15.2%). For medication errors
instead, “Other antiseptics and disinfectants” (9/358; 2.5%)
with all cases involving tosylchloramide sodium (9/9; 100.0%)
(Figures 2, 3). Percentage distribution of adverse drug reactions
(classified by SOC) distributed by abuse, overdose, misuse,
medication error, and occupational exposure was provided in
Figure 4. At the first quality control by CPPRC, 125 (34.9%)
out of 358 ICSRs did not have a codification of abuse,
overdose, misuse, medication error and occupational exposure
or codifications were performed erroneously (Figure 1). Errors
that were more frequently identified in ICSRs included
misclassification of cases of abuse as overdose (10/125; 8.0%) and
misclassification of medication errors as overdose (7/125; 5.6%)
or abuse (7/125; 5.6%) (Table 3).
Predictors of
Un-classification/Misclassification of
Abuse, Overdose, Misuse, Medication
Error and Occupational Exposure
Years following the introduction of the Directive 2010/84/EU
and the Regulation (EU) No 1235/2010 were found protective
for un-classification or misclassification of abuse, overdose,
misuse, medication error, and occupational exposure. Such
errors reduced from July 2nd 2012 to December 31th 2017
with a statistically significant lower probability of having un-
classification or misclassification of 25% for each year subsequent
to 2012 (ROR 0.75, 95%CI 0.59–0.95; p-value: 0.02). Compared
to pharmaceutical companies for which no codification errors
were identified, patients/citizens (as reporters) had a 24.88
higher odd (ROR 24.88, 95%CI 1.82–449.95; p-value: 0.02)
of performing un-classification or misclassification of abuse,
overdose, misuse, medication error and occupational exposure.
Similarly, anti-poison center and pharmacists (as reporters)
had a 10.15 (ROR 10.15, 95%CI 1.19-118.72; p-value: 0.04)
and 7.50 higher odd (ROR 7.50, 95%CI 1.28-67.38; p-value:
0.04) of performing aforementioned errors, respectively. For
ICSRs having adverse drug reactions classified as “Nervous
system disorders,” such as coma, asthenia, sleepiness and
psychomotor agitation, it was found a 66% lower odd (ROR 0.34,
95%CI 0.13-0.81; p-value: 0.02) of having un-classification or
misclassification. ICSRs that reported “drugs for cardiovascular
disorders” as suspected (mainly vitamin K antagonist and
β-blockers) were found to have a 2.74 higher odd (ROR
2.74, 95%CI 1.04-7.38; p-value: 0.04) of un-classification or
misclassification if compared to “Benzodiazepine derivatives”
(Figure 5).
Impact of Codification Errors on Signal
Detection Activities
Codification errors were associated with the underestimation of
PRR, ROR, RRR, and IC’ estimates in the identification of the
safety signal “Benzodiazepine derivatives/abuse” (Figure 6).
DISCUSSION
This study is a set of initiatives proposed by CPPRC to
promote drug safety (Parretta et al., 2014; Mascolo et al.,
2016; Rafaniello et al., 2016; Sessa et al., 2016a,c, 2017a).
Aforementioned initiatives include strengthening of the Regional
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FIGURE 4 | Percentage distribution of adverse drug reactions (classified by System Organ Class) reported in ICSRs deriving from abuse, misuse, medication error
and occupational exposure that were sent through Campania Region spontaneous system from July 2nd 2012 to December 31th 2017.
TABLE 3 | Representative examples of codification errors for cases deriving from abuse, misuse, medication error, and occupational exposure.
Codification at the first
ICSR evaluation
Final codification following a
case-by-case re-valuation
Representative examples of
codification errors
Number of ICSRs
Overdose Abuse i.e., attempted suicides 10
Overdose Medication error i.e., unintentional administration/use 7
Abuse Medication error i.e., unintentional administration/use 7
Abuse Misuse i.e., intentional use a topical solution
per os
2
Individual Case Safety Report (ICSR).
pharmacovigilance system by introducing more clearly defined
roles and responsibilities of stakeholders. Moreover, the early
identification of preventable adverse drug reactions occurring
on the Regional territory and the promotion of an appropriate
use of medicinal products. By revaluating all ICSRs sent through
Campania Region spontaneous reporting system from July 2nd
2012, we found an exponential increase of ICSR reporting
abuse, overdose, misuse, medication error and occupational
exposure in the first 2 years following the implementation of
the Regulation EU/1235/2010 and the Directive 2010/84/EU.
The majority of cases derived from a condition of abuse
with “Benzodiazepines derivatives” and in particular alprazolam,
lorazepam, and delorazepam. Our results are in line with
those obtained by Leporini and colleagues in Calabria Region
(southern Italy), despite aforementioned authors obtained such
results from an active pharmacovigilance project and, therefore,
using a different methodology (Leporini et al., 2017). In
fact, as opposed to Leporini and colleagues, we performed a
passive Pharmacovigilance project that focused exclusively on
the identification of ICSRs deriving from the non-normal use
of medical products. Our study, provide a detailed description
of demographic and clinical characteristics of aforementioned
cases and a detailed revision of the most reported suspected
drugs and adverse drug reactions for each non-normal condition
of use. It should be highlighted that as opposed to Leporini
et al., we performed a case-by-case validation of all ICSRs in
order to re-assess “non-normal” conditions in ICSRs. In fact, we
did not rely on codifications that were performed prior to the
data recording in RNF. Despite aforementioned differences, in
accordance with our results, Leporini and colleagues observed
that the majority of cases derived from abuse, mainly with
benzodiazepines. In this regard, it is not surprising to find
benzodiazepines derivatives in cases of abuse. In fact, for our
Region, we previously described such phenomenon (Sessa et al.,
2016b) and, in the scientific community, it is widely accepted
that benzodiazepines derivatives usage could be associated with
abuse, self-harm or attempt suicide (Longo and Johnson, 2000;
Neale and Smith, 2007). For medication errors instead, we
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FIGURE 5 | Predictors of un-classification or misclassification of ICSRs deriving from abuse, misuse, medication error and occupational exposure that were sent
through Campania Region spontaneous system from July 2nd 2012 to December 31th 2017.
found that the “Other antiseptics and disinfectants” and in
particular topical solutions of tosylchloramide sodium, was
the most reported in such cases. For our Country (Italy),
this phenomenon was described in the scientific literature.
In fact, in the Italian pharmaceutical market there are liquid
formulations of tosylchloramide sodium for disinfection of
skin’ wounds or external genitalia. Aforementioned formulations
are granules that need to be dissolved in water. Being such
formulations similar to granulates of other active ingredients that
are supposed to be used orally, patients tends to get confused
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FIGURE 6 | Impact of codification errors on signal detection activities for the signal “Benzodiazepine derivatives/abuse.” PRR, Proportional Reporting Ratio; ROR,
Reporting Odds Ratio; RRR, Relative Reporting Ratio; IC, Information Component.
ingesting the topic solution of tosylchloramide sodium orally
(Lariccia et al., 2013). By looking at the percentage distribution
of adverse drug reactions, as expected, the most representative
were “type A” adverse drug reactions (or rather dose-dependent
adverse drug reactions according to Rawlins and Thompson
classification Rawlins, 1977). This result should be considered
in virtue of abuse/overdose as the most reported “non-normal
use” condition in Campania Region spontaneous reporting
system. Interestingly, 1 out of 3 ICSRs deriving from abuse,
misuse, medication error, and occupational exposure did not
have a codification or codifications were performed erroneously.
Errors were frequent during the first 2 years following the
introduction of the new Pharmacovigilance legislation however,
with a statistically significant reduction over time, especially in
the last 2 years. In this regards, we believe that a great impact
for this result was played by education activities performed by
CPPRC and AIFA on both the Regional and National territory
(Sessa et al., 2016b,d, 2017b). Among predictors for codification
errors, ICSRs sent by patients/citizens were found associated
with an increased odd of un-classification or misclassification
of abuse, overdose, misuse, medication error, and occupational
exposure. Whenever confirmed with additional studies, our
result opens a “Pandora box” in terms of potential differences
in the quality of ICSRs sent by patients/citizens. In fact, we
proved that in contrast with what was previously found for
ICSRs reporting “normal” use of drugs (Rolfes et al., 2017), the
quality of ICSRs sent by patients could be lower than healthcare
professionals when there is the need to codify “non-normal”
conditions (Rolfes et al., 2017). Analogously, a crucial aspect
of our results is that anti-poison center and pharmacists’ error
trend did not overlap with the general trend. In fact, anti-
poison center and pharmacists showed a progressive reduction
of the correct codification. In this regard, we believe that
corrective measures are necessary. In fact, we will organize ad-
hoc courses to train anti-poison center and pharmacists on
the proper codification of adverse drug reactions deriving from
the non-normal use of medicinal products. Additionally, in
our study, we found specific clinical scenarios for which it
was more likely to perform a codification error. In particular,
ICSRs that reported “drugs for cardiovascular disorders” as
suspected (mainly vitamin K antagonist and β-blockers) were
found to have a 2.74 higher odd of un-classification or
misclassification if compared to cases reporting “Benzodiazepine
derivatives.” In these cases, codification errors mainly involved
misclassification of abuse or overdose. We believe that a possible
explanation for aforementioned errors (but more generally for
all codification errors involving abuse/overdose) could be the
actual definitions of abuse/overdose. If we imagine a clinical
scenario where a patient treated with vitamin K antagonist
use an excessive dose of this drug for attempting suicide
and we look at the current definition of overdose and abuse,
both definitions partially cover this scenario making hard the
choice of the correct codification for non-trained reporter. In
particular, for the definition of overdose “. . .administration of
a quantity of a medicinal product given per administration
or cumulatively, which is above the maximum recommended
dose” while for the definition of abuse “. . . intentional excessive
use of a medicinal product, which is accompanied by harmful
physical or psychological effects” (European Medicine Agency,
2017). Additionally, we believe that a cause for aforementioned
errors could be the inconsistency between the new “regulatory”
definition of “abuse/overdose” and the currently available
definitions (i.e., pharmacological, psychiatric, etc.) for which
there is a lack of consensus (Rinaldi et al., 1988; World
Health Organization, 1994; Substance Abuse and Mental Health
Services Administration, 2001; Cicero et al., 2007; Katz et al.,
2007; Bronstein et al., 2008). Finally, another interesting result
of our study is the quantification of the underestimation of
PRR, ROR, RRR, and IC’ estimates due to codification errors
while identifying the known safety signal “Benzodiazepine
derivatives/abuse.” In particular, independently of the measure of
disproportionality used, codification errors were associated with
an underestimation of disproportionality measures’ estimates.
This effect was statistically significant for PRR (as confidence
intervals with and without considering codification errors did
not overlap), while it was statistically insignificant for ROR,
RRR, and IC. In this regard, it could not be excluded that
whenever measures to minimize codification errors will not be
implemented, these errors might play a key role in masking
new safety signal for which magnitude will not be massive as
for the safety signal “Benzodiazepine derivatives/abuse.” In this
regard, we believe that to mitigate aforementioned errors might
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be beneficial to include “attempted suicide” among “non-normal
use” scenarios.
CONCLUSION
In conclusion, this study found that in Campania Region
(southern Italy) there was an exponential increase of ICSR
reporting abuse, overdose, misuse, medication error and
occupational exposure following the implementation of the new
Pharmacovigilance legislation with an improvable proportion
of cases misclassified/unclassified. Moreover, this study found
that ICSRs sent by patients/citizens were associated with an
increased odd of un-classification or misclassification and that
un-classification or misclassification had a relevant impact on
signal detection activities. Educational activities will be organized
to guarantee the correct codification of abuse, misuse, overdose,
medication error, and occupational exposure on the Regional
territory.
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